Summary & Overview
HCPCS Level II J3241: Injection, teprotumumab-trbw, 10 mg
HCPCS Level II code J3241 denotes a 10 mg unit of teprotumumab-trbw, an intravenously administered monoclonal antibody used in specialty infusion settings. As a high-cost biologic, accurate coding and consistent payer recognition are important for reimbursement, clinical documentation, and care coordination. This code matters nationally because it applies to specialty infusion providers, hospital outpatient departments, and payers managing access to complex biologic therapies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical purpose and service setting, typical billing considerations, and where to expect payer coverage variations. The publication outlines benchmarks and policy context relevant to billing J3241, highlights common modifiers used in practice (input list), and summarizes implications for service line reporting and revenue cycle workflows.
This summary is intended to orient clinicians, billing professionals, and policy analysts to the primary clinical description, typical sites of service, and the payer landscape for HCPCS Level II code J3241. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J3241 represents an injection of teprotumumab-trbw, billed per 10 mg unit. This biologic product is administered as an intravenous infusion for systemic therapy. The service type is injectable biologic infusion therapy, and the typical site of service is an outpatient infusion center or hospital outpatient department.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult diagnosed with thyroid eye disease (TED) experiencing progressive proptosis, diplopia, orbital pain, or corneal exposure despite standard therapy. The patient presents to an outpatient infusion center affiliated with an ophthalmology or endocrinology practice. A multidisciplinary visit (ophthalmologist and endocrinologist) documents indication, baseline ophthalmic exam including proptosis measurement, visual acuity, and diplopia assessment, and baseline laboratory tests and vital signs.
On the infusion day the patient is registered, allergy and consent are confirmed, and pre-infusion vitals are obtained. Teprotumumab-trbw is supplied in vials and prepared by pharmacy as an intravenous infusion; J3241 describes the billed drug unit (10 mg). The patient receives pre-medications per local protocol if required, is connected to the infusion pump, and monitored for infusion reactions. Post-infusion observation includes reassessment of vitals and ocular symptoms. Documentation includes drug name teprotumumab-trbw, dose in mg, number of J3241 units administered, infusion start and stop times, lot numbers, and any adverse events. Typical sites of service are hospital outpatient departments, physician office infusion suites, or independent infusion centers. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|